CAS 8047-67-4|Iron sucrose

Introduction：Basic information about CAS 8047-67-4|Iron sucrose, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Iron sucrose BiologicalActivity
3. Chemical & Physical Properties
4. Toxicological Information
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
5. Safety Information
6. Customs
7. Synonyms

Common Name	Iron sucrose
CAS Number	8047-67-4	Molecular Weight	736.059
Density	/	Boiling Point	766.4ºC at 760 mmHg
Molecular Formula	C₁₈H₂₄Fe₂O₂₄	Melting Point	MORE THAN 51ºC
MSDS	/	Flash Point	431.2ºC

Names

Name	Iron saccharate
Synonym	More Synonyms

Iron sucrose BiologicalActivity

Description	Iron sucrose (Iron saccharate) is a intravenous iron preparation and a pro-oxidant agent. Iron sucrose has the potential for iron deficiency anemia treatment[1][2][3][4].
Related Catalog	Research Areas >>Metabolic Disease
In Vitro	Intravenous Iron sucrose results in a statistically significant increase in hemoglobin, mean corpuscular volume, serum iron, ferritin, and % iron saturation, with a corresponding decrease in total iron binding capacity[1]. In vitro survival assays show that 10 mM ascorbate exposure (2h) clonogenically inactivated 40-80% of exponentially growing colon cancer cell lines (HCT116 and HT29). When colon cancer cells are treated in the presence or absence of 250 µM Iron sucrose, then rinsed, and treated with 10 mM ascorbate, the cells demonstrate increased levels of labile iron that results in significantly increased clonogenic cell killing, compared to pharmacological ascorbate alone[2]. The expression levels of intracellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) and adhesion of U937 cells increased in Iron sucrose-treated human aortic endothelial cells through upregulated NADPH oxidase (NOx) and NF-κB signaling. Iron sucrose significantly induces a time-dependent increase in intracellular ROS production in HAECs between 1 and 3 hours at a concentration of 160 μg/mL, but the effect diminished at 4 hours[3].
In Vivo	Iron sucrose significantly increases tissue superoxide production, expression of tissue cell adhesion molecules, and endothelial adhesiveness in mice with subtotal nephrectomy. Iron sucrose exacerbates atherosclerosis in the aorta of ApoE-/- mice with uninephrectomy[3].
References	[1]. Kristiyana Kaneva, et al. Intravenous Iron Sucrose for Children With Iron Deficiency Anemia. J Pediatr Hematol Oncol. 2017 Jul;39(5):e259-e262. [2]. Kristin E Brandt, et al. Augmentation of Intracellular Iron Using Iron Sucrose Enhances the Toxicity of Pharmacological Ascorbate in Colon Cancer Cells. Redox Biol. 2018 Apr;14:82-87. [3]. Ko-Lin Kuo, et al. Iron Sucrose Accelerates Early Atherogenesis by Increasing Superoxide Production and Upregulating Adhesion Molecules in CKD. J Am Soc Nephrol. 2014 Nov;25(11):2596-606. [4]. Richard A Zager, et al. Combined Iron Sucrose and Protoporphyrin Treatment Protects Against Ischemic and Toxin-Mediated Acute Renal Failure. Kidney Int. 2016 Jul;90(1):67-76.

Chemical & Physical Properties

Boiling Point	766.4ºC at 760 mmHg
Melting Point	MORE THAN 51ºC
Molecular Formula	C₁₈H₂₄Fe₂O₂₄
Molecular Weight	736.059
Flash Point	431.2ºC
Exact Mass	735.935608
PSA	483.54000
InChIKey	ADQSUDSYBZBMFT-UHFFFAOYSA-H
SMILES	O=C([O-])C(O)C(O)C(O)C(O)C(=O)[O-].O=C([O-])C(O)C(O)C(O)C(O)C(=O)[O-].O=C([O-])C(O)C(O)C(O)C(O)C(=O)[O-].[Fe+3].[Fe+3]

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: NO7700000

CHEMICAL NAME :: Iron oxide, saccharated

CAS REGISTRY NUMBER :: 8047-67-4

LAST UPDATED :: 199512

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 180 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,193,1982

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 150 mg(Fe)/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 10,375,1955 ** TUMORIGENIC DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1560 mg/kg/13W-I

TOXIC EFFECTS :: Tumorigenic - Carcinogenic by RTECS criteria Reproductive - Tumorigenic effects - other reproductive system tumors

REFERENCE :: BJCAAI British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947- Volume(issue)/page/year: 60,708,1989

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 148 gm/kg/74W-I

TOXIC EFFECTS :: Tumorigenic - neoplastic by RTECS criteria Tumorigenic - tumors at site of application

REFERENCE :: BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 1,947,1959

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 104 gm/kg/13W-I

TOXIC EFFECTS :: Tumorigenic - equivocal tumorigenic agent by RTECS criteria Tumorigenic - tumors at site of application

REFERENCE :: JNCIAM Journal of the National Cancer Institute. (Washington, DC) V.1-60, 1940-78. For publisher information, see JJIND8. Volume(issue)/page/year: 24,109,1960

TYPE OF TEST :: TD - Toxic dose (other than lowest)

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 150 gm/kg/I

TOXIC EFFECTS :: Tumorigenic - equivocal tumorigenic agent by RTECS criteria Blood - lymphoma, including Hodgkin's disease Tumorigenic - tumors at site of application

REFERENCE :: BECCAN Annual Report--Cancer Research Campaign. (Cancer Research Campaign, 2 Carlton House Terrace, London SW1Y 5AR, UK) V.1- 1924- Volume(issue)/page/year: 40,30,1962 *** REVIEWS *** IARC Cancer Review:Animal Limited Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 2,161,1973 IARC Cancer Review:Human No Adequate Data IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 2,161,1973 IARC Cancer Review:Group 3 IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,56,1987 TOXICOLOGY REVIEW PEXTAR Progress in Experimental Tumor Research. (S. Karger AG, Postfach CH-4009 Basel, Switzerland) V.1- 1960- Volume(issue)/page/year: 12,102,1969

Safety Information

HS Code	3004909090

Customs

HS Code	3004909090

Synonyms

Venofer

ferrivenin

Sucrofer

EINECS 232-464-7

MFCD00166305

Fesin

Hippiron

Iron(3+) D-glucarate (2:3)

ironsugar

iviron

proferrin

feojectin

Recommended......